SHARE:
Modernizing Life Science Manufacturing: How
analytics, IoT and the cloud are rewriting drug production
2
M
anufac turing is one of the most
challenging environments in the
pharmaceutical industry. Companies
m u s t q u i c k l y, e f f i c i e n t l y a n d
consistently execute complex processes in compliance
with evolving regulations. Any missteps in these
processes can lead to shortages or compromised
safety of drug therapies which are critical to patient's
lives. Today, enhanced data collection through
connected IoT devices, data analytics and machine
learning in the cloud are giving companies near
real-time insights into their plants, equipping them
to manage these pressures and modernize their
manufacturing pipelines.
Therapeutic manufacturers are recognizing the
efficiency-enhancing potential of data analytics at
a time when pricing pressures and portfolio shifts
are forcing them to rethink their operations. Having
built their manufacturing footprints in the era of
blockbuster pills and capsules, leading pharmaceutical
companies now see biotherapeutics, cell and gene
therapies and other emerging drug modalities as
critical to their future. However, these new modalities
are considerably more complex and costly to make
than traditional pharmaceutical products and require
the mastery of new technologies, processes and supply
chain requirements.
Inc re me nt a l i mprove me nt s i n manu f a c tu r i ng
margins at all plants, whether they make pills or
biotherapeutics, are more important than ever. In
some cases, manufacturing is now a way to gain a
clear competitive advantage, from improving yields to
decreasing production time, and can have a significant
impact on the bottom line.
In light of the pressure to make therapeutics better,
faster and cheaper, forward-thinking companies are
seeing this as an opportunity to use new data analytics
and the cloud to modernize their manufacturing
operations and supply chain. To do so, manufacturers
